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Introduction 
In 1979, Sir John Charnley accurately predicted that joint sepsis would be the major hurdle 
facing the orthopedic community of his future.  Indeed, decades later, studies are confirming Dr. 
Charnley’s foresight, as they indicate that 0.7%- 12%  of primary joint replacement cases result in 
periprosthetic joint infection.  However, large or small the percentage, PJI is presently a devastating 
risk or reality to TJA patients, and an elaborate obstacle facing clinicians and surgeons around the 
world.  
Periprosthetic joint infection is the leading cause of failure of total knee arthroplasty and the 
third leading cause of failure of total hip arthroplasty1.  While a timely and accurate diagnosis in these 
cases significantly aids in eradicating the infection,  the treatment option chosen is arguably most 
telling indicator of success in overcoming PJI1.  Therefore, this critical decision is paramount in not 
only successfully eliminating the infection, but also  limiting the likelihood of a reinfection as well as 
continued challenge for both the patient and the surgeon.       
 In order to overcome PJI and yield a painless, functioning joint, the most appropriate treatment 
for each patient should be decided through careful consideration of the interaction which exists 
between a variety of host factors, organism factors, and surgical factors in each specific case.  In 
North America, the two-stage exchange is currently the most preferred treatment method for chronic 
PJI.  However,  surgeons may decide on a more fitting solution based the outcomes of clinical 
assessments and laboratory results.  Further treatment options commonly implemented also include 
the following: antibiotic suppression alone,  debridement in addition to the use of antibiotics, and one-
stage exchange arthroplasty.   Salvage operation such as arthrodesis or above the knee amputation 
is reserved for patients with failed multiple operations and unreconstructible joint.  
 Dialogue regarding the treatment of PJI is incomplete without mention of biofilm, the formation of 
which occludes the course of treatment.  Initially requiring only a few microorganisms to adhere to the 
implant, the generation of mature biofilm can take up to 3 weeks2 and serves as a communication 
pathway for the organism3.  Impenetrable by the host immune system as well as antimicrobial 
agents4, biofilm not only presents an obvious hurdle in the treatment of PJI, but also remains 
undetected and often complicates diagnosis.  
 
Treatment Options  
Antibiotic Suppression Alone 
This is rarely an option in management of PJI. However, in extremely sick and frail patients 
who may not tolerate surgical treatment antibiotic suppression may be employed to control infection 
and prevent systemic progression. For this treatment to have an effect, the prosthesis needs to be 
well fixed and the organism needs to be susceptible to oral antibiotics.  
Irrigation and Debridement 
Although one study indicated that 29% of THA patients5 that had debridement with prosthesis 
retention resulted in failure6-8 surgical debridement with component retention plus antibiotic 
administration is a viable option in certain scenarios.  For example, postoperative patients that 
present with acute symptoms of infection, up to 48 hours after their procedure9, may be a good 
candidate for this treatment method if there is also an identified, susceptible organism.   As shown by 
a multicenter study conducted by the Periprosthetic Infection Consortium (PIC) 10, the importance of 
identifying the specific type of pathogen inflicting the infection should not be minimized, since 
debridement fails in 60-90% of cases when the infection  is caused by Methicillin Resistant 
Staphylococcus aureus (MRSA) 11.  Due to such undesirable results, this treatment method may not 
the best option for patients with MRSA infection even at acute stages.  Also, debridement is not 
recommended in cases where there is a loose prosthesis and inadequate soft tissue coverage9.  It is 
important to note that debridement is contraindicated if the time from the primary arthroplasty to the 
diagnosis of PJI exceeds 30 days, or if the patient has previously undergone this surgical treatment in 
the same joint5,12.   
One-stage Exchange 
One stage exchange arthroplasty, as the name implies, involves removal of the infected 
prosthesis through debridement of the joint followed by reimplantation with a new prosthesis. This 
surgical procedure is more often employed in Europe, with some centers reporting very high success 
rate for eradication of infection13. In North America this procedure is usually employed in elderly, frail 
patients who may not be able to undergo multiple operations. The success rate of this procedure, and 
others for that matter, is improved if the patient is not immunocompromised, and there is good soft 
tissue coverage of the infected joint. In addition susceptibility of the organism also impacts the 
outcome of this surgical intervention directly. 
The obvious advantage of this method is that the patient has a component resection and 
reimplantation during one surgical procedure.  Having one multipart operation such as this, results in 
a single overall recovery period that is generally shorter.  Additionally, and in consequence with 
having one operation , there is also an  estimated, overall decrease in expenses associated with this 
treatment option.  A one-stage exchange procedure is contraindicated, however, when the patient is 
in poor health or the infection is caused by resistant bacteria.  Furthermore, this procedure is 
inadvisable if the joint cannot be reconstructed adequately due to mechanical issues or limitations 
due poor soft tissue coverage.  Despite its overall limited success, the chances of improving results 
with a direct exchange procedure  increases with the use of local antibiotic cement.  One study 
indicated this success rate to be around 82%  for cases using antibiotic cement compared to a rate of 
only 58% in cases that forgo its application14.    
 
Two-stage Exchange 
Two-stage exchange arthroplasty involves removal of the prosthesis and insertion of antibiotic 
impregnated cement spacer into the joint during the first stage of the procedure. Patient then is 
brought back for reimplantation once tissues are healed and infection is deemed to be eradicated15. 
This surgical option is the work horse of treating chronic PJI. Although historically this surgical 
intervention was believed to have success rate above 90% or so, in recent years the success of this 
procedure is believed to be in decline6. There is  multitude of reasons that may explain the decline in 
success of this surgical procedure, the most important of which is the increase in the incidence of PJI 
caused by resistant organisms16. The incidence of such resistant organisms, like MRSA and MRSE, 
has doubled and quadrupled respectively, over the past decade9.  Although PJI cases caused by 
MRSA are 9.2 times more likely to fail17,  the two-stage exchange revision has been the best option 
thus far, as the failure rate of these cases is even greater with other treatments such as an irrigation 
and debridement where 70% result in failure11.       
It is imperative for the success of this procedure, that careful monitoring of the infection take place 
at each stage of treatment.  Aggressive debridement is a necessary during the first step, along with 
the removal of all foreign material, including any PMMA cement.  A spacer laden with antibiotics is 
then put in place of the removed prosthesis.  High doses of thermostable antibiotics should be used in 
the spacer. At our institution we utilize 4 grams of vancomycin and 3.6 grams of tobramycin in each 
40 gram pack of PMMA. The patient is also given antibiotics for a minimum duration of 6 weeks 
postoperatively. 
The next stage, reimplantation, is advised when the serological markers, namely erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) returns to normal or had trended down 
considerably. In about 20% of PJI cases, the serological markers, in particular ESR, may still be 
abnormal at the time of reimplantation. Though desirable, the abnormal values do not prohibit the 
success of reimplantation significantly2.  Prior to reimplantation, the joint may need to be aspirated in 
patients with abnormal serological markers or those suspected of harboring infection. At our 
institution any patients with previously failed two-stage exchange arthroplasty is aspirated prior to 
reimplantation arthroplasty, regardless of the results of serological markers. It is imperative that 
aspiration is performed when patient has been off the antibiotics for at least two weeks. When 
performed, the joint aspirate should be sent for neutrophil count and neutrophil percentage in addition 
to culture18. 
During reimplantation it is critical that perioperative antibiotics is administered and if cemented 
components are used, antibiotic is also added to the cement. During reimplantation the traffic in the 
operating room needs to be controlled in a very strict fashion. Prior to reimplantation through 
debridement and irrigation of the joint needs to be performed and multiple tissue and fluid samples 
sent for culture. In patients who have undergone reimplantation and an organism is isolated from the 
intraoperative culture (even in broth), postoperative intravenous antibiotics needs to be administered.  
In situations where the infection is uncontrollable, reimplantation is contraindicated.  Furthermore, 
if the patient is medically unfit (8% to 10% of PJI patients), has neurological or vascular impairments, 
or a soft tissue deficiency persists, reimplantation is not recommended either.  In general, results from 
our studies indicate that the true success rate of the two-stage exchange, is around 65-70%, when 
success is defined as no infection, no mechanical failure or need for reoperation19.    
 
Salvage Procedures 
However rare, intricate and difficult cases do exist where reimplantation is not an option.  
These patients may have uncontrollable infections where salvage of the joint looks close to 
impossible.  Additionally, they may be immunocompromised or they may have insufficient bone stock 
and muscle function necessary for successful joint reconstruction.  The salvage operation in these 
cases is usually resection arthroplasty or in extremely rare circumstances disarticulation of the joint. 
Arthrodesis of the hip joint is almost never performed under these circumstances.   
Patients with resection arthroplasty of the hip may be able to ambulate limited distances. 
Patients usually suffer an extensive limb length discrepancy and may have limited to no abductor 
function. Hip disarticulation may be performed for patients with uncontrollable infection and systemic 
manifestation of sepsis. It may also be employed in patients with extensive soft tissue deficiency in 
whom hygiene may be an issue. Patients with systemic sepsis and extensive osteomyelitis may also 
require this salvage operation. Patients undergoing hind quarter amputation or hip disarticulation may 
not be able to ambulate. 
 
Conclusion 
For several decades total hip arthroplasty has increased the quality of life of patients receiving this 
procedure by reducing pain and increasing function of the arthritic hip joint.  However, when infection 
follows a THA, it compromises the success of this procedure entirely.  In order to successfully 
eradicate the infection and reconstruct the joint, it is imperative that the best treatment method is 
employed.  An assortment of variables, specific to each case, shapes the viability of each treatment 
option in PJI cases.  Thus, the success of any treatment option first rests in the hands of the clinician 
who integrates the surgical factors with those which evolve at the host-organism interface, in order to 
control and eradicate the infection.  
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